国家医保局答21：加强医保和商保保障范围、结算等协同

Group 1 - The core viewpoint of the article is the introduction of measures to support the high-quality development of innovative drugs in China, focusing on issues such as accessibility and reimbursement [1] - The National Healthcare Security Administration and the National Health Commission released a document titled "Several Measures to Support the High-Quality Development of Innovative Drugs," which includes 16 measures across five areas to support the entire chain of innovative drug development, access, hospital use, and multi-payment systems [1] Group 2 - The National Healthcare Security Administration is accelerating the establishment of a multi-tiered medical security system, which includes a unified medical insurance information platform and a three-tiered basic medical security system [2] - The "1+3+N" multi-tiered medical security system aims to enhance the effectiveness of basic medical insurance, critical illness insurance, and medical assistance while promoting the role of commercial health insurance and other supplementary protections [2] - Collaboration between basic medical insurance and commercial health insurance will focus on areas such as coverage scope, data sharing, settlement processes, and regulatory oversight to support the development of innovative drugs [3]